Edaravone and Argatroban Stroke Therapy Study for Acute Ischemic Stroke
Status:
Completed
Trial end date:
2008-05-01
Target enrollment:
Participant gender:
Summary
Edaravone, a free radical scavenger, is a novel neuroprotective agent, and argatroban is a
selective thrombin inhibitor. Both the drugs were approved by the Japanese Government, and
have frequently been used for the treatment of acute brain infarction in Japan. The effect of
combination therapy of these drugs, however, has not yet been elucidated. This study will
test the safety and efficacy of the combination therapy with these agents in patients with
acute non-cardioembolic and non-lacunar ischemic stroke.
Phase:
Phase 4
Details
Lead Sponsor:
Combination Therapy for Acute Ischemic Stroke Study Group